Murine B16-OVA [199,200], SM1 [201] and BRAF mutant D4M3.A and YUMM1.7 [202] melanoma cell lines are other examples that have been used to test in vivo the therapeutic effect of drug candidates. The gene discussed is BRAF; the disease is melanoma.